01919nas a2200217   4500008004100000022001400041245009000055210006900145260000800214300000600222490000700228520123200235653001501467653001301482653001601495653001701511653001501528100001901543700001901562856012001581       2022                        eng d  a2190-572X00aCOVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis0 aCOVID19 associated mucormycosis evolving technologies for early   cJAN  a60 v123 aThe post-coronavirus disease (COVID-19) mucormycosis is a deadly addition to the pandemic spectrum. Although it's a rare, aggressive, and opportunistic disease, the associated morbidity and mortality are significant. The complex interplay of factors aggravating CAM is uncontrolled diabetes, irrational and excessive use of antibiotics, steroids, and an impaired immune system. Recently, India has been witnessing a rapid surge in the cases of coronavirus disease-associated mucormycosis (CAM), since the second wave of COVID-19. The devastating and lethal implications of CAM had now become a matter of global attention. A delayed diagnosis is often associated with a poor prognosis. Therefore, the rapid and early diagnosis of infection would be life-saving. Prevention and effective management of mucormycosis depend upon its early and accurate diagnosis followed by a multimodal therapeutic approach. The current review summarizes an array of detection methods and highlights certain evolving technologies for early and rapid diagnosis of CAM. Furthermore, several potential management strategies have also been discussed, which would aid in tackling the neglected yet fatal crisis of mucormycosis associated with COVID-19.10aBiosensors10aCOVID-1910aDiagnostics10aMucormycosis10aProbiotics1 aSamson, Rachel1 aDharne, Mahesh  uhttps://library.ncl.res.in/content/covid-19-associated-mucormycosis-evolving-technologies-early-and-rapid-diagnosis